AGEN
ANALYST COVERAGE11 analysts
BUY
+125.1%upside to target
L $7.00
Med $7.00consensus
H $8.00
Buy
873%
Hold
327%
8 Buy (73%)3 Hold (27%)0 Sell (0%)
Full report →
Key MetricsTTM
Market Cap$129.51M
Revenue TTM
Net Income TTM
Free Cash Flow
Gross Margin52.1%
Operating Margin6.6%
Net Margin52.2%
Return on Equity-23.1%
Return on Assets34.6%
Debt / Equity
Current Ratio0.38
EPS TTM
PRICE
Prev Close
3.16
Open
3.30
Day Range3.06 – 3.35
3.06
3.35
52W Range2.71 – 7.34
2.71
7.34
9% of range
VOLUME & SIZE
Avg Volume
804.9K
FUNDAMENTALS
P/E Ratio
1.5x
Value territory
EPS (TTM)
Div Yield
No dividend
Beta
1.65
High vol
TECHNICAL
RSI (14)
39
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 24
DEx-Dividend
In 90 days
Aug 21
PDividend Pay
In 128 days
Sep 28

AGEN News

About

agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Garo Armen
Robin G. TaylorChief Commercial Officer
Todd Jude YanceyMember of Advisory Board & Chief Strategic Advisor
Tracy Mazza ClementeChief People Officer
Garo H. ArmenFounder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman
Steven J. O'DayChief Medical Officer
Zack ArmenVice President of Investor Relations & Corporate Development
Stefanie Perna-NacarChief Communications & Government Relations Officer
Jennifer S. BuellDirector and President & Chief Executive Officer of MiNK Therapeutics
Craig WinterChief Information Officer
Kamel DjazouliHead of Medical Affairs
Austin CharetteSenior Director, Financial Reporting and Compliance & Principal Accounting Officer